155 related articles for article (PubMed ID: 27325561)
61. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
[TBL] [Abstract][Full Text] [Related]
62. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
63. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
64. Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy.
Rodríguez-Berriguete G; Torrealba N; Ortega MA; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Guil-Cid M; Fraile B; Royuela M
BMC Cancer; 2015 Oct; 15():809. PubMed ID: 26507126
[TBL] [Abstract][Full Text] [Related]
65. Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: A propensity score matched study.
Byun SS; Lee M; Hong SK; Lee H
PLoS One; 2019; 14(11):e0224671. PubMed ID: 31697718
[TBL] [Abstract][Full Text] [Related]
66. Incremental value of magnetic resonance imaging for clinically high risk prostate cancer in 922 radical prostatectomies.
Jeong IG; Lim JH; You D; Kim MH; Choi HJ; Kim JK; Cho KS; Hong JH; Ahn H; Kim CS
J Urol; 2013 Dec; 190(6):2054-60. PubMed ID: 23791890
[TBL] [Abstract][Full Text] [Related]
67. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
68. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
Bauer JJ; Connelly RR; Seterhenn IA; Deausen J; Srivastava S; McLeod DG; Moul JW
J Urol; 1998 Mar; 159(3):929-33. PubMed ID: 9474185
[TBL] [Abstract][Full Text] [Related]
69. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.
Moul JW; Connelly RR; Lubeck DP; Bauer JJ; Sun L; Flanders SC; Grossfeld GD; Carroll PR
J Urol; 2001 Oct; 166(4):1322-7. PubMed ID: 11547066
[TBL] [Abstract][Full Text] [Related]
70. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
71. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
72. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
73. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
74. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.
Maj-Hes AB; Mathieu R; Özsoy M; Soria F; Moschini M; Abufaraj M; Briganti A; Roupret M; Karakiewicz PI; Klatte T; Shariat SF
Urol Oncol; 2017 Jul; 35(7):460.e1-460.e8. PubMed ID: 28460801
[TBL] [Abstract][Full Text] [Related]
75. Ki-67 expression predicts biochemical recurrence after radical prostatectomy in the setting of positive surgical margins.
Shahait M; Nassif S; Tamim H; Mukherji D; Hijazi M; El Sabban M; Khauli R; Bulbul M; Abou Kheir W; El Hajj A
BMC Urol; 2018 Mar; 18(1):13. PubMed ID: 29506507
[TBL] [Abstract][Full Text] [Related]
76. Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.
Stamey TA; Yemoto CM; McNeal JE; Sigal BM; Johnstone IM
J Urol; 2000 Apr; 163(4):1155-60. PubMed ID: 10737486
[TBL] [Abstract][Full Text] [Related]
77. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
[TBL] [Abstract][Full Text] [Related]
78. A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease.
Severi G; FitzGerald LM; Muller DC; Pedersen J; Longano A; Southey MC; Hopper JL; English DR; Giles GG; Mills J
Cancer Med; 2014 Oct; 3(5):1266-74. PubMed ID: 24909936
[TBL] [Abstract][Full Text] [Related]
79. Expression changes in the stroma of prostate cancer predict subsequent relapse.
Jia Z; Rahmatpanah FB; Chen X; Lernhardt W; Wang Y; Xia XQ; Sawyers A; Sutton M; McClelland M; Mercola D
PLoS One; 2012; 7(8):e41371. PubMed ID: 22870216
[TBL] [Abstract][Full Text] [Related]
80. High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker.
Liu S; Hawley SJ; Kunder CA; Hsu EC; Shen M; Westphalen L; Auman H; Newcomb LF; Lin DW; Nelson PS; Feng Z; Tretiakova MS; True LD; Vakar-Lopez F; Carroll PR; Simko J; Gleave ME; Troyer DA; McKenney JK; Brooks JD; Liss MA; Stoyanova T
Sci Rep; 2024 Jan; 14(1):486. PubMed ID: 38177207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
